Illumina Sees At Least 10% Total EPS Growth Over Next 3-Years; Unveils Strategy Aimed At 8%-9% Sales Growth By 2027

Author: Benzinga Newsdesk | August 13, 2024 11:00am
-- Company poised to accelerate revenue growth into high single digits over next three years, enabled by core genomics portfolio -- Innovations to enable development of transformative applications using multiomics -- Illumina to offer higher quality insights to customers, helping them improve the overall end-to-end workflow experience and lower cost -- Delivering double digit to teens non-GAAP diluted earnings per share growth 2025-2027 -- Illumina and the Broad Institute of MIT and Harvard announce new research partnership to advance single-cell sequencing SAN DIEGO, Aug. 13, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today is hosting a Strategy Update for investors to present its strategy and three-year financial outlook that features accelerating revenue growth and significant margin expansion.

Posted In: ILMN